SR Medical Technology (SEHK:108) Stock May Be 33% Undervalued On Cash Flow

SR Medical Technology has seen its share price move sharply in recent years, which naturally raises a question for anyone looking at the stock today. Are the cash flows that SR Medical Technology can generate over time enough to support where the share price now sits?

• Over the past 3 years the share price has delivered a very large gain, so a lot now depends on how well that performance lines up with the cash the business can produce.

• The company’s ability to turn its operations into steady free cash flow may support ongoing investment needs without stretching the balance sheet, which matters for any valuation built on its future cash generation.

• Prefer to judge SR Medical Technology on sales? See why SR Medical Technology’s 25.0x P/S tells a different valuation story.

For investors, the debate is whether SR Medical Technology’s current share price is in line with the intrinsic value suggested by its cash flows.

If you are weighing SR Medical Technology against other cash flow focused ideas, a targeted stock screen built around 193 high quality undervalued stocks can give you a structured starting list for further research.

Is SR Medical Technology Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model used here looks at the cash SR Medical Technology can return to shareholders over time and then discounts that back to today. On the latest twelve month numbers, the group produced free cash flow of about HK$289.7 million, which gives the valuation framework real operating cash rather than just accounting profit.

The projections used in this DCF assume that SR Medical Technology’s free cash flow grows from that base and then gradually slows into a more mature path over the following decade. Based on those cash flow estimates, the model indicates an intrinsic value that is substantially above the current HK$2.86 share price. In other words, the DCF implies the market is currently pricing SR Medical Technology below the level suggested by its projected cash generation. Find out what SR Medical Technology could be worth using our Discounted Cash Flow (DCF) estimate.

The SR Medical Technology Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives pick up where the SR Medical Technology valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to hold for the shares to be worth meaningfully more or less than today’s price, and they sit on the stock’s Community page. Each narrative links a specific fair value to a clear story about SR Medical Technology’s possible catalysts and risks so you can track which version seems to be unfolding over time.

A clear, number-driven narrative on SR Medical Technology gives you a concrete yardstick for where its growth, margins and execution would need to land for today’s valuation debate to make sense. Putting those assumptions in writing makes it easier to test them against actual results over time and adjust your thesis with less emotion and more discipline.

Share your own Narrative for SR Medical Technology and set out the assumptions behind your valuation.

SR Medical Technology: why the people in charge matter as much as the price

SR Medical Technology’s cash flows tell only part of the story, because the outcomes you care about depend heavily on who is steering the business and how their rewards line up with yours. See who runs SR Medical Technology and how they are paid.

This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include 0108.HK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]